GILD
Gilead Sciences, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Neutral
+18/100
Last price
143.63
▼ 1.00 (0.69%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
144.63
Prev close
144.63
Day high
146.14
Day low
142.60
Volume
3.72M
Market cap
$178.84B
P/E (TTM)
—
52W range
114.02 – 157.29
Day trading desk
Gap from prior close
-0.00%
Prior close 144.63
VWAP
144.13
-0.35% from price
Relative volume
0.84×
Normal
Session range
2.55%
142.50 – 146.14
Position in range
31%
Mid range
ATR (14D)
3.46
2.41% of price
Prior day high
145.16
PDH
Prior day low
142.79
PDL
Bid / ask spread
—
Quote not published
Session volume
5.11M
Avg 6.06M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-4.66%
-6.6%
1M
-4.48%
-5.6%
3M
+6.19%
+1.7%
6M
+3.91%
-14.3%
YTD
+17.51%
+3.3%
1Y
+27.99%
+11.6%
3Y
+92.46%
+10.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on GILD open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
-58.76K
Net selling
Buy transactions
23
120.24K shares
Sell transactions
19
179.00K shares
Net transactions
+42
Buys less sells
Sell : buy shares
1.5 : 1
Mixed
Insider-held shares
1.36M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 22, 26 | BURKHART ERIN Officer |
— | 2.22K | — | Direct |
| Sep 15, 26 | MERCIER JOHANNA Officer |
SELL | 3.00K | $432.65K | Direct |
| Sep 15, 26 | DICKINSON ANDREW D Chief Financial Officer |
SELL | 3.00K | $435.87K | Direct |
| Sep 10, 26 | CAIN WETTAN KEELEY M General Counsel |
— | 590 | — | Direct |
| Sep 10, 26 | MERCIER JOHANNA Officer |
— | 2.80K | — | Direct |
| Sep 10, 26 | O'DAY DANIEL PATRICK Chief Executive Officer |
— | 8.78K | — | Direct |
| Sep 10, 26 | BERGER DIETMAR P. Officer |
— | 533 | — | Direct |
| Sep 10, 26 | DICKINSON ANDREW D Chief Financial Officer |
— | 2.80K | — | Direct |
| Sep 1, 26 | O'DAY DANIEL PATRICK Chief Executive Officer |
SELL | 15.00K | $2.23M | Direct |
| Aug 26, 26 | WELTERS ANTHONY Director |
SELL | 18.00K | $2.68M | Direct |
| Aug 26, 26 | WELTERS ANTHONY Director |
CONVERSION | 18.00K | $1.10M | Direct |
| Aug 20, 26 | BLUESTONE JEFFREY Director |
CONVERSION | 5.00K | $335.21K | Direct |
| Aug 20, 26 | BLUESTONE JEFFREY Director |
SELL | 5.00K | $725.08K | Direct |
| Aug 17, 26 | MERCIER JOHANNA Officer |
CONVERSION | 25.00K | $1.68M | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BARTON JACQUELINE K |
Director | 27.20K | Stock Award(Grant) |
BERGER DIETMAR P. |
Officer | 19.52K | Conversion of Exercise of derivative security |
DICKINSON ANDREW D |
Chief Financial Officer | 164.10K | Sale |
MANWANI HARISH |
Director | 15.02K | Stock Award(Grant) |
MERCIER JOHANNA |
Officer | 116.68K | Sale |
O'DAY DANIEL PATRICK |
Chief Executive Officer | 581.68K | Conversion of Exercise of derivative security |
PARSEY MERDAD V |
Officer | 82.85K | Conversion of Exercise of derivative security |
PATTERSON SANDRA |
Officer | 39.45K | Conversion of Exercise of derivative security |
TELMAN DEBORAH H |
General Counsel | 43.68K | Conversion of Exercise of derivative security |
WILFONG DIANE E |
Officer | 46.26K | Conversion of Exercise of derivative security |
Fundamentals
Market cap$178.84B
Enterprise value$200.12B
Revenue (TTM)$30.46B
Gross profit$24.25B
EBITDA$14.60B
Net income$-3.24B
EPS (TTM)$-2.64
Free cash flow$9.77B
Total cash$4.88B
Total debt$26.25B
Book value / share$9.53
Shares outstanding1.24B
Float1.24B
Short % of float1.48%
Dividend yield2.27%
Beta (5Y)0.33
Valuation & profitability ratios
Trailing P/E—
Forward P/E14.58
PEG ratio2.15
Price / sales—
Price / book15.13
EV / revenue6.57
EV / EBITDA13.71
Gross margin79.60%
Operating margin33.68%
Profit margin-10.64%
Return on equity-20.68%
Return on assets14.09%
Debt / equity223.47
Current ratio1.27
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $29.44B | $28.75B | $27.12B | $27.28B | +2.4% |
| Operating revenue | $29.44B | $28.75B | $27.12B | $27.28B | +2.4% |
| Cost of revenue | $6.23B | $6.25B | $6.50B | $5.66B | -0.3% |
| Gross profit | $23.21B | $22.50B | $20.62B | $21.62B | +3.1% |
| Research & development | $5.80B | $5.91B | $5.72B | $4.98B | -1.8% |
| Selling, general & admin | $5.71B | $6.00B | $6.06B | $5.67B | -4.9% |
| Total operating expense | $11.51B | $11.91B | $11.78B | $10.65B | -3.4% |
| Operating income | $11.70B | $10.60B | $8.84B | $10.97B | +10.4% |
| Net interest income | -$675.00M | -$696.00M | -$568.00M | -$829.00M | +3.0% |
| Pre-tax income | $9.80B | $690.00M | $6.86B | $5.81B | +1,319.7% |
| Tax provision | $1.29B | $211.00M | $1.25B | $1.25B | +509.5% |
| Net income | $8.51B | $480.00M | $5.67B | $4.59B | +1,672.9% |
| Net income to common | $8.51B | $480.00M | $5.67B | $4.59B | +1,672.9% |
| Basic EPS | 6.84 | 0.38 | 4.54 | 3.66 | +1,700.0% |
| Diluted EPS | 6.78 | 0.38 | 4.50 | 3.64 | +1,684.2% |
| EBIT | $10.82B | $1.67B | $7.80B | $6.75B | +549.1% |
| EBITDA | $13.58B | $4.43B | $10.50B | $8.85B | +206.3% |
| Basic shares | 1.24B | 1.25B | 1.25B | 1.25B | -0.2% |
| Diluted shares | 1.25B | 1.25B | 1.26B | 1.26B | 0.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $7.56B | $9.99B | $6.08B | $5.41B | -24.3% |
| Cash & short-term investments | $9.61B | $11.57B | $7.26B | $6.38B | -16.9% |
| Accounts receivable | $4.91B | $4.42B | $4.66B | $4.78B | +11.2% |
| Inventory | $1.77B | $1.71B | $1.79B | $1.51B | +3.7% |
| Total current assets | $18.34B | $19.17B | $16.09B | $14.44B | -4.3% |
| Property, plant & equipment | $5.61B | $5.41B | $5.32B | $5.47B | +3.5% |
| Goodwill & intangibles | $25.29B | $28.26B | $34.77B | $37.21B | -10.5% |
| Total assets | $59.02B | $58.99B | $62.13B | $63.17B | +0.0% |
| Total current liabilities | $11.81B | $12.00B | $11.28B | $11.24B | -1.6% |
| Current debt | $2.81B | $1.81B | $1.80B | $2.27B | +54.7% |
| Long-term debt | $22.13B | $24.90B | $23.19B | $22.96B | -11.1% |
| Total debt | $24.94B | $26.71B | $24.99B | $25.23B | -6.6% |
| Total liabilities | $36.41B | $39.75B | $39.38B | $41.96B | -8.4% |
| Retained earnings | $13.73B | $11.50B | $16.30B | $15.69B | +19.4% |
| Shareholder equity | $22.70B | $19.33B | $22.83B | $21.24B | +17.4% |
| Working capital | $6.53B | $7.17B | $4.80B | $3.21B | -8.9% |
| Net tangible assets | -$2.59B | -$8.93B | -$11.94B | -$15.97B | +71.0% |
| Shares issued | 1.24B | 1.25B | 1.25B | 1.25B | -0.4% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $8.51B | $480.00M | $5.61B | $4.57B | +1,672.9% |
| Depreciation & amortisation | $2.76B | $2.77B | $2.69B | $2.10B | -0.3% |
| Stock-based compensation | $894.00M | $835.00M | $766.00M | $637.00M | +7.1% |
| Change in working capital | -$3.95B | -$880.00M | -$2.30B | -$1.76B | -348.6% |
| Operating cash flow | $10.02B | $10.83B | $8.01B | $9.07B | -7.5% |
| Capital expenditure | -$563.00M | -$523.00M | -$585.00M | -$728.00M | -7.6% |
| Investing cash flow | -$4.79B | -$3.45B | -$2.27B | -$2.47B | -39.0% |
| Share buybacks | -$1.92B | -$1.15B | -$1.00B | -$1.40B | -67.1% |
| Dividends paid | -$4.00B | -$3.92B | -$3.81B | -$3.71B | -2.2% |
| Financing cash flow | -$7.75B | -$3.43B | -$5.13B | -$6.47B | -125.6% |
| Free cash flow | $9.46B | $10.30B | $7.42B | $8.34B | -8.2% |
| End cash position | $7.56B | $9.99B | $6.08B | $5.41B | -24.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $7.80B | $6.96B | $7.92B | $7.77B | $7.08B | +12.1% |
| Operating revenue | $7.80B | $6.96B | $7.92B | $7.77B | $7.08B | +12.1% |
| Cost of revenue | $1.58B | $1.45B | $1.62B | $1.57B | $1.50B | +9.3% |
| Gross profit | $6.22B | $5.51B | $6.30B | $6.20B | $5.58B | +12.9% |
| Research & development | $1.76B | $1.37B | $1.58B | $1.35B | $1.49B | +28.6% |
| Selling, general & admin | $1.92B | $1.45B | $1.73B | $1.36B | $1.36B | +32.4% |
| Total operating expense | $3.69B | $2.82B | $3.31B | $2.70B | $2.86B | +30.5% |
| Operating income | $2.54B | $2.69B | $2.99B | $3.50B | $2.72B | -5.7% |
| Net interest income | -$202.00M | -$145.00M | -$160.00M | -$168.00M | -$181.00M | -39.3% |
| Pre-tax income | -$10.25B | $2.58B | $2.08B | $3.64B | $2.43B | -497.4% |
| Tax provision | $242.00M | $559.00M | -$105.00M | $589.00M | $468.00M | -56.7% |
| Net income | -$10.50B | $2.02B | $2.18B | $3.05B | $1.96B | -619.3% |
| Net income to common | -$10.50B | $2.02B | $2.18B | $3.05B | $1.96B | -619.3% |
| Basic EPS | -8.45 | 1.63 | 1.76 | 2.46 | 1.57 | -618.4% |
| Diluted EPS | -8.45 | 1.61 | 1.74 | 2.43 | 1.56 | -624.8% |
| EBIT | -$10.01B | $2.82B | $2.33B | $3.90B | $2.68B | -454.9% |
| EBITDA | -$9.31B | $3.51B | $3.02B | $4.58B | $3.37B | -365.3% |
| Basic shares | 1.24B | 1.24B | 1.24B | 1.24B | 1.25B | +0.1% |
| Diluted shares | 1.24B | 1.25B | 1.25B | 1.25B | 1.25B | -0.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $3.18B | $7.63B | $7.56B | $7.33B | $5.14B | -58.3% |
| Cash & short-term investments | $3.18B | $7.64B | $9.61B | $7.35B | $5.21B | -58.4% |
| Accounts receivable | $5.05B | $4.74B | $4.91B | $5.09B | $4.78B | +6.6% |
| Inventory | $1.95B | $1.91B | $1.77B | $1.78B | $1.82B | +2.0% |
| Total current assets | $13.95B | $18.64B | $18.34B | $17.87B | $14.72B | -25.2% |
| Property, plant & equipment | $5.83B | $5.64B | $5.61B | $5.50B | $5.46B | +3.5% |
| Goodwill & intangibles | $22.35B | $24.70B | $25.29B | $26.28B | $26.88B | -9.5% |
| Total assets | $49.36B | $56.28B | $59.02B | $58.53B | $55.72B | -12.3% |
| Total current liabilities | $11.02B | $9.47B | $11.81B | $12.30B | $11.19B | +16.3% |
| Current debt | $2.41B | $1.31B | $2.81B | $2.81B | $2.81B | +83.9% |
| Long-term debt | $23.83B | $20.86B | $22.13B | $22.14B | $22.14B | +14.2% |
| Total debt | $26.25B | $22.17B | $24.94B | $24.94B | $24.95B | +18.4% |
| Total liabilities | $37.62B | $32.85B | $36.41B | $37.08B | $36.13B | +14.5% |
| Retained earnings | $2.20B | $14.13B | $13.73B | $12.82B | $11.32B | -84.4% |
| Shareholder equity | $11.83B | $23.52B | $22.70B | $21.54B | $19.68B | -49.7% |
| Working capital | $2.92B | $9.17B | $6.53B | $5.58B | $3.53B | -68.1% |
| Net tangible assets | -$10.52B | -$1.18B | -$2.59B | -$4.74B | -$7.21B | -791.4% |
| Shares issued | 1.24B | 1.24B | 1.24B | 1.24B | 1.24B | -0.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$10.50B | $2.02B | $2.18B | $3.05B | $1.96B | -619.3% |
| Depreciation & amortisation | $698.00M | $689.00M | $687.00M | $686.00M | $691.00M | +1.3% |
| Stock-based compensation | $231.00M | $218.00M | $230.00M | $230.00M | $225.00M | +6.0% |
| Change in working capital | $36.00M | -$711.00M | -$604.00M | -$297.00M | -$2.01B | +105.1% |
| Operating cash flow | $3.57B | $2.54B | $3.33B | $4.11B | $827.00M | +40.4% |
| Capital expenditure | -$140.00M | -$117.00M | -$205.00M | -$147.00M | -$107.00M | -19.7% |
| Investing cash flow | -$10.35B | $1.77B | -$1.83B | -$427.00M | -$2.12B | -684.6% |
| Share buybacks | -$355.00M | -$419.00M | -$230.00M | -$435.00M | -$527.00M | +15.3% |
| Dividends paid | -$1.03B | -$1.04B | -$994.00M | -$1.00B | -$994.00M | +1.1% |
| Financing cash flow | $2.34B | -$4.24B | -$1.26B | -$1.49B | -$1.57B | +155.3% |
| Free cash flow | $3.43B | $2.43B | $3.12B | $3.96B | $720.00M | +41.5% |
| End cash position | $3.18B | $7.63B | $7.56B | $7.33B | $5.14B | -58.3% |
Options analytics
Put / call volume
1.45
Put-heavy session
Put / call open interest
0.62
Positioning, not flow
Max pain
146.00
+1.2% from spot
ATM implied vol
35.4%
Nearest strike to spot
Skew (10% OTM)
+11.5%
Puts bid over calls
Call volume
131
Contracts, this expiry
Put volume
190
Contracts, this expiry
Heaviest call OI
146.00
606 contracts
Heaviest put OI
146.00
648 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -7.25 | -6.75 | +6.9% |
| Mar 2026 | 1.91 | 2.03 | +6.2% |
| Dec 2025 | 1.81 | 1.86 | +2.8% |
| Sep 2025 | 2.14 | 2.47 | +15.7% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 2.15 | 22 | $7.77B | -0.0% |
| Next quarter | 2.19 | 20 | $8.13B | +2.6% |
| Current year | -0.43 | 27 | $30.70B | +4.3% |
| Next year | 9.89 | 26 | $32.68B | +6.5% |
Analyst targets & ownership
Mean target$158.65
High target$180.00
Low target$123.00
Implied upside10.46%
Analyst count26
ConsensusBUY
Strong buy / Buy6 / 15
Hold5
Sell / Strong sell0 / 1
Held by insiders0.11%
Held by institutions92.20%
Institutions holding3.07K
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
148.56
-3.32% from price
SMA 20
148.22
-2.69% from price
SMA 50
143.78
+0.32% from price
SMA 100
136.69
+5.08% from price
SMA 200
136.94
+5.32% from price
EMA 12
147.59
-2.68% from price
EMA 26
147.13
-2.37% from price
EMA 50
144.26
-0.43% from price
RSI (14)
42.7
Neutral
MACD (12,26,9)
0.46
Hist -1.12
ATR (14)
3.46
2.40% of price
Realised vol 30D
19.7%
Annualised
Bollinger upper
154.03
20, 2σ
Bollinger lower
142.42
20, 2σ
50 / 200 cross
Golden
143.78 vs 136.94
Trend bias
Above 200
+5.32%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.33
Less volatile than market
Correlation to SPY
0.16
Largely independent
Realised vol 30D
19.7%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-22.0%
Peak to trough
Max drawdown 5Y
-29.4%
Peak to trough
ATR 14
3.46
2.40% of price
Beta (reported)
0.33
5Y monthly, from filing
Short interest
Shares short
18.30M
Prior 23.18M
Change vs prior
-21.0%
Shorts covering
% of float
1.48%
Normal
% of shares out
1.48%
Against total outstanding
Days to cover
3.5
Liquid
Float
1.24B
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 10, 26 | HSBC | MAINTAINED | Buy | Buy |
| Aug 5, 26 | RBC Capital | MAINTAINED | Sector Perform | Sector Perform |
| Aug 5, 26 | Cantor Fitzgerald | MAINTAINED | Overweight | Overweight |
| Aug 5, 26 | Needham | MAINTAINED | Buy | Buy |
| Jul 29, 26 | Barclays | MAINTAINED | Equal-Weight | Equal-Weight |
| Jul 27, 26 | Morgan Stanley | MAINTAINED | Overweight | Overweight |
| Jul 21, 26 | Leerink Partners | DOWNGRADE | Outperform | Market Perform |
| Jul 8, 26 | Morgan Stanley | MAINTAINED | Overweight | Overweight |
| Jul 7, 26 | RBC Capital | MAINTAINED | Sector Perform | Sector Perform |
| Jul 7, 26 | Truist Securities | MAINTAINED | Buy | Buy |
| Jul 6, 26 | Cantor Fitzgerald | MAINTAINED | Overweight | Overweight |
| Jul 6, 26 | HSBC | UPGRADE | Hold | Buy |
Dividends & splits
Forward rate$3.28 / yr
Forward yield2.27%
5-year avg yield3.33%
Payout ratio43.46%
Ex-dividend dateSep 15, 2026
Next pay dateSep 29, 2026
Last split2:1
Split dateJan 28, 2013
SEC filings
Annual Report of Proxy Voting Record of Registered Management Investment Companies filed on Form N-PX
N-PX · 2026-08-26
Periodic Financial Reports
10-Q · 2026-08-06
Corporate Changes & Voting Matters
8-K · 2026-08-04
Corporate Changes & Voting Matters
8-K · 2026-05-20
Periodic Financial Reports
10-Q · 2026-05-07
Corporate Changes & Voting Matters
8-K · 2026-05-04
Corporate Changes & Voting Matters
8-K · 2026-04-28
Tender Offer/Acquisition Reports
SC TO-T/A · 2026-04-17
Headlines
Cognizant, Gilead Sign 5-Year Tech Extension Covering DevOps, AI Tools
MT Newswires · 13h ago
Entera Appoints Global BioPharma Executive Laura Hamill to Its Board of Directors, Expanding Commercial Expertise
GlobeNewswire · 14h ago
Compugen Highlights COM701 Ovarian Trial, Expands AI Platform Into Tumor Targets
MarketBeat · 1d ago
BioMarin Appoints Cara Bauer as Chief People Officer
PR Newswire · 1d ago
Nurix Therapeutics, Gilead Sciences Agree on Two-Year Research Term Extension for Oncology Program
MT Newswires · 2d ago
Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences
GlobeNewswire · 2d ago
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
Zacks · 4d ago
Sector Update: Healthcare
MT Newswires · 4d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.